. NO does not mediate inhibitory neural responses in sheep airway and bronchial vascular smooth muscle. J. Appl. Physiol. 84(3): 809-814, 1998.-Endogenous nitric oxide (NO) influences acetylcholineinduced bronchovascular dilation in sheep and is a mediator of the airway smooth muscle inhibitory nonadrenergic, noncholinergic neural response in several species. This study was designed to determine the importance of NO as a neurally derived modulator of ovine airway and bronchial vascular smooth muscle. We measured the response of pulmonary resistance (RL) and bronchial blood flow (Q br) to vagal stimulation in 14 anesthetized, ventilated, open-chest sheep during the following conditions: 1) control; 2) infusion of the ␣-agonist phenylephrine to reduce baseline Q br by the same amount as would be produced by infusion of N -nitro-Larginine (L-NNA), a NO synthase inhibitor; 3) infusion of L-NNA (10 Ϫ2 M); and 4) after administration of atropine (1.5 mg/kg). The results showed that vagal stimulation produced an increase in RL and Q br in periods 1, 2, and 3 (P Ͻ 0.01) that was not affected by L-NNA. After atropine was administered, there was no increase in Q br or RL. In vitro experiments on trachealis smooth muscle contracted with carbachol showed no effect of L-NNA on neural relaxation but showed a complete blockade with propranolol (P Ͻ 0.01). In conclusion, the vagally induced airway smooth muscle contraction and bronchial vascular dilation are not influenced by NO, and the sheep's trachealis muscle, unlike that in several other species, does not have inhibitory nonadrenergic, noncholinergic innervation.
IN A PREVIOUS STUDY from our laboratory, Sasaki et al. (12) have shown that acetylcholine (ACh) injected directly into the bronchial circulation of anesthetized sheep causes bronchoconstriction and an increase in bronchial arterial blood flow. The bronchial vascular dilation was mediated, in part, by release of nitric oxide (NO) because inhibition of NO synthase (NOS) attenuated the dilator response as well as decreasing baseline blood flow. The ACh-induced bronchoconstriction was not, however, enhanced after NOS inhibition. This suggests that when NO is released from the bronchial vasculature it does not influence airway smooth muscle contraction. Another source of NO, as a potential regulator of bronchial blood flow (Q br) and airway tone, is nonadrenergic, noncholinergic (NANC) nerve endings (4) .
The neurotransmitter that mediates the inhibitory NANC response of airway and vascular smooth muscle has been characterized as NO in a variety of species (1-4, 7, 14, 17). In addition, it has been shown that release of NO can modulate bronchoconstriction in some animals. For instance, inhibition of NOS causes an enhanced response to vagal stimulation in the guinea pig (3) . Vagal nerve stimulation has been shown to cause bronchial vascular dilation in pigs (11) and cats (10) . This vasodilatory effect was not blocked by administration of atropine in pigs (11) and was only partially inhibited by atropine in cats (10) . This result suggests the presence of a NANC inhibitory system. As yet, the presence of a NANC inhibitory system has not been conclusively demonstrated in either airways or bronchial vasculature in the ovine lung. In 1982, Sheller and Brigham (13) showed that the adrenergic nervous system was an important inhibitory mechanism of airway smooth muscle contraction in sheep. However, because the role of NO as a neurotransmitter had not been described at that time, it was not possible to verify the mechanism of the observed residual nonadrenergic relaxation. Because NO has since been identified as the major NANC inhibitory mediator in the airways (4), we have assessed its importance as a neurally derived modulator of ovine airway smooth muscle tone in vitro and in vivo. In addition, we have determined whether NO contributes to the bronchial vascular dilation that is caused by vagal nerve stimulation in this species.
METHODS

Intact Sheep
Surgical protocol. We studied 14 Dorset-cross rams (25-30 kg) that were placed in the supine position.
All studies were done according to the Canadian guidelines for the use and care of animals. Anesthesia was induced by injection of thiopental sodium (15-20 mg/kg iv). A tracheotomy tube was inserted, and the sheep were ventilated with 50% O 2 and air at a tidal volume (VT) of 12-15 ml/kg and a rate of ϳ15 breaths/min. Anesthesia was maintained by using a continuous infusion of thiopental sodium (5-10 mg·kg Ϫ1 ·h Ϫ1 iv).
A catheter was inserted in the left carotid artery to measure systemic arterial blood pressure and to obtain blood samples for measurement of arterial blood-gas tensions. With the use of fluoroscopy, we inserted a thermistor-tipped, triplelumen catheter into the right jugular vein and advanced the catheter to the pulmonary artery for measurement of pulmonary arterial and wedge pressure. Cardiac output was measured by using the thermodilution technique. A double-lumen catheter was placed in the superior vena cava for continuous infusion of the anesthetic (proximal port) and administration of intravenous fluids and drugs (distal port) as necessary. All vascular pressures were referenced to the level of the left atrium. A 5-cm length of the right and left vagus nerve was carefully exposed.
Sheep were paralyzed by intravenous injection of 2 mg pancuronium bromide. The chest was then opened by a left thoracotomy incision between the 5th and 6th ribs, and 3 cmH 2 O positive end-expiratory pressure was applied. To measure bronchial arterial blood flow, we carefully exposed the bronchial artery. A 2-mm flow probe (Transonic Systems, Ithaca, NY) was placed around the bronchoesophageal artery. The probe was then connected to the flowmeter, and Q br was recorded by using a low-pass-filter setting of 10 Hz. A 5-Fr cobra catheter was introduced into the right femoral artery. With the use of fluoroscopy and injection of small amounts of radiocontrast material, we advanced the catheter so that the tip was in the orifice of the bronchoesophageal artery. Q br was recorded continuously during placement of the cobra catheter to ensure that it was situated so that it did not alter the blood flow. To prevent clotting in the cobra catheter and in the bronchial artery, heparin (4,000 U) was given intravenously; this was supplemented by giving 1,000 U every 2 h. All pressure and flow tracings were displayed continuously on a video display unit and were recorded, as necessary, by using a digital recording system (Ray Tech, Vancouver, BC, Canada).
As soon as an intravenous line was in place, ibuprofen [␣-methyl-4-(2-methylpropyl)-benzeneacetic acid; 15 mg/kg in 0.5 M saline; Sigma Chemical, St. Louis, MO] was administered to block any vasodilatory effects of prostaglandins. After surgery was completed, an intravenous bolus (2 mg/kg) of the ␤-adrenergic blocker DL-propranolol hydrochloride [1-(isopropylamino)-3-(1-naphthyloxy)-2-propanolol; Sigma Chemical] was administered, followed by a continuous infusion of 20 µg·kg Ϫ1 · min Ϫ1 propranolol.
To measure lung resistance (RL, cmH 2 O·l Ϫ1 · s), airflow was measured by using a Fleisch no. 1 pneumotachometer, and tracheal pressure was measured from a side port (2 mm ID) of the tracheostomy tube with a differential pressure transducer (model MP45; Validyne, Northridge, CA). Because the chest was open, tracheal pressure was compared with atmospheric pressure to give transpulmonary pressure (PL). RL was calculated, using the computer program ANADAT (RHTInfoDat, Montreal, Canada), by multiple linear-regression curve fitting of PL ϭ EV ϩ RL ·V ϩ Po, where V is volume, E is lung elastance, V is airflow, and Po is a constant equal to positive end-expiratory pressure of 3 cmH 2 O (8).
Experimental protocol. When the sheep were stabilized, ϳ30 min after completion of the surgical procedures, we recorded baseline measurements of cardiac output, systemic arterial blood pressure, pulmonary arterial pressure, Q br, arterial blood-gas tensions and RL. Vagal stimulation was applied during four different experimental conditions: 1) postvagotomy; 2) bronchial arterial infusion of the ␣-agonist phenylephrine (5 ϫ 10 Ϫ6 to 5 ϫ 10 Ϫ7 M); 3) bronchial arterial infusion of the NOS inhibitor L-NNA (1 ϫ 10 Ϫ2 M); and 4) after administration of atropine (atropine sulfate salt, 1.5 mg/kg; Sigma).
After baseline measurements of vascular pressures, cardiac output, RL, Q br, and arterial blood-gas tensions (control) were recorded, a bilateral vagotomy was performed. The cut ends of the nerves were coated in mineral oil to keep them moist. We used a constant-current stimulator, repetitive mode (5-10 s), and stimulated the nerve at a frequency of 8 Hz and a pulse width of 2 ms. The duration of stimulation varied between 3 and 20 s (compliance voltage of ϳ35 V), and the current (0.4-4 A) was varied to give the greatest increase in Q br associated with the least fall in systemic arterial blood pressure (there was always 1 vagus that produced a greater increase in Q br for a smaller fall in blood pressure). After the optimal response had been determined, all of the stimulus settings remained the same for the rest of the experiment. PERIOD 1: POSTVAGOTOMY. Before the vagus nerve was stimulated, physiological measurements were recorded as described above. The protocol for stimulation of the vagus nerve was as follows: 15 s before stimulation, we started recording measurements of blood pressure, Q br, and RL. The vagus was stimulated by using the optimal stimulator settings as described above, and the peak increase in Q br was recorded. Q br usually returned to the baseline value within 2-3 min after vagal stimulation. After ϳ5 min, the vagus was stimulated again, and repeat measurements of Q br were obtained to ensure reproducibility of the response. Three such measurements were usually made, and the average value of the closest two measurements was used in the data analysis.
PERIOD 2: INFUSION OF PHENYLEPHRINE. Phenylephrine was given in 9 of the 14 sheep, because we knew, from results of a previous study from our laboratory (12) , that infusion of L-NNA produces a consistent decrease in baseline Q br. Therefore, to test whether simple vasoconstriction with a contractile agonist would attenuate the vasodilatory response to vagal stimulation, we gave sufficient phenylephrine to decrease Q br by the same amount as we anticipated would occur on infusion of L-NNA. It usually took 5-10 min of infusion of phenylephrine to reduce Q br to this anticipated level (ϳ50% of the baseline value). The vagus was then stimulated, and measurements were repeated.
PERIOD 3: INFUSION OF L-NNA. L-NNA (10 Ϫ2 M) was infused for 20 min via the cobra catheter into the bronchial artery, as previously described (12) . The infusion rate was set at onetenth of the Q br (2-3 ml/min) and adjusted at 5-min intervals as Q br decreased. Infusion of L-NNA was continued while physiological parameters were recorded, the vagus was stimulated, and measurements were repeated. PERIOD 4: ATROPINE. Atropine (1.5 mg/kg iv) was given as a bolus; after ϳ20 min, the vagus was stimulated and recordings were made.
At the end of the experiment, the sheep were deeply anesthetized and killed by intravascular injection of saturated potassium chloride.
Excised Airways
On the morning of the study, we obtained from the slaughterhouse six fresh lungs from Dorset-cross sheep (sheep weight, ϳ40 kg). Trachealis muscle segments were obtained by excising them from the cartilage and cutting them into strips ϳ3 mm wide and 15 mm long. The trachealis muscle strips were mounted under 2-g preload in a jacketed water bath and were incubated at 37°C in Krebs-Henseleit solution (composition in mM: 118.4 NaCl, 4. 2 . After a 1-h equilibration period, frequencyresponse curves to electrical field stimulation were obtained by using platinum wire electrodes. Settings for the stimulator were based on the work of Kannan and Johnson (7) and were optimized for maximal responses with our apparatus. Settings were 70 V, 1-ms pulse duration, for 20 s at frequencies between 1 and 32 Hz. Contractile responses (force generated) were measured by Grass FTO3 transducers during the 20-s stimulation period and were recorded on Beckman chart recorders. The strips were incubated for 20 min in atropine (0.3 µM). Responses to 1, 4, 8, and 32 Hz were again obtained, with a 5-min period between each stimulation. The tissue was then washed once, and 5 µM carbachol was added to precontract the muscle. One segment of tissue was then incubated with N G -nitro-L-arginine (32 µM) for 30 min (tissue A), and a control tissue (tissue B) was incubated with Krebs-Henseleit solution. Relaxant responses to electrical field stimulation were then assessed at 1, 4, 8, and 32 Hz. Tissue A was then treated with 1 µM propranolol for 30 min; tissue B remained a control tissue and received an additional amount of KrebsHenseleit solution. Repeat responses were obtained at 1, 4, 8, and 32 Hz. Tetrodotoxin (1 µM) was then added to the bath for 10 min, and responses were repeated, using the same frequencies as described above. Finally, theophylline (1 µM) was added to the bath to determine the maximal amount of smooth muscle relaxation. Whenever possible, duplicate tissues were studied, so that four tissues from each sheep were used.
Data Analysis
Intact sheep. The data were expressed as absolute values and as a percentage of baseline. A paired t-test was used to test whether there was a difference in Q br before and after vagotomy. The responses to vagal stimulation were compared as absolute changes and as percent changes during the four experimental periods. To test whether vagal stimulation increased Q br, bronchial vascular resistance, and RL, baseline and peak Q br (ml/min), bronchial vascular resistance (mmHg · ml Ϫ1 · min), and RL (cmH 2 O·l Ϫ1 · s) were analyzed by using a one-tailed, paired t-test. A two-way analysis of variance was used to compare baseline Q br and RL in the four different experimental periods (postvagotomy, phenylephrine, L-NNA, and after atropine). After application of a square-root transformation of the data, the absolute and percent increases in Q br and bronchial vascular resistance produced by vagal stimulation during the four experimental periods were analyzed by using a repeated-measures analysis of variance with two repeating factors. The sequential rejective Bonferroni procedure was used to correct for multiple comparisons and multiple t-tests. A corrected P value Ͻ0.05 was considered to be significant.
Excised airways. Contractile responses of the trachealis muscle were expressed as percentage of the tension developed at 32 Hz (which was found to be maximal in preliminary experiments). Relaxation responses after electrical field stimulation were expressed as percentage of the maximal theophylline-induced relaxation. The effect of L-NNA, propranolol, and tetrodotoxin was assessed by using a repeated-measures analysis of variance. A P value Ͻ0.05 was considered significant.
RESULTS
Intact Sheep
Q br decreased from 21.5 Ϯ 10 (SD) to 16 Ϯ 7 ml/min after vagotomy (P Ͻ 0.05). Data for individual sheep for Q br (ml/min) obtained just before (baseline) and at the peak response to vagal nerve stimulation (peak) for the four experimental periods after vagotomy are shown in Table 1 . The values (means Ϯ SD) for Q br and bronchial vascular resistance at baseline and in response to vagal stimulation are shown in Table 2 . Baseline values of Q br measured during periods 2, 3, and 4 (phenylephrine, L-NNA, and atropine, respectively) were all less (P Ͻ 0.01) than during period 1 (postvagotomy). There were no differences in baseline values of Q br between periods 2, 3, and 4. In response to vagal stimulation, there was an increase in Q br (P Ͻ 0.01) in periods 1, 2, and 3. After atropine, there was no increase in Q br after vagal stimulation. The increase in blood flow in response to vagal stimulation was greater in period 1 than in period 2 (P Ͻ 0.05) and period 3 (P Ͻ 0.01). There was no difference in the increase in Q br between periods 2 and 3. When the increase in Q br was expressed as a percentage of baseline, there were no differences between periods 1, 2, and 3.
The values (means Ϯ SD) for bronchial vascular resistance at baseline and in response to vagal stimulation are shown for the four experimental periods in Table 2 . Data are expressed as absolute values and as percent change. Because infusion of phenylephrine and L-NNA produced only a slight increase in baseline values of systemic arterial blood pressure (1 Ϯ 5 and 5 Ϯ 14 mmHg, respectively), the changes in bronchial vascular resistance were similar to the changes in Q br. Table 3 shows data (means Ϯ SD) for RL (cmH 2 O·l Ϫ1 · s) obtained just before (baseline) and at the peak response to vagal nerve stimulation (peak) as well as the absolute and percent changes from the baseline value for the four experimental periods. There was no difference in baseline RL for the four experimental periods. Vagal stimulation produced a small increase in the absolute and percent increase in RL in periods 1, 2, and 3, but there was no change in RL after administration of atropine. There was no difference in the absolute or percentage increase in RL during periods 1, 2, and 3. Table 4 shows values (means Ϯ SD) for hemodynamics, arterial blood-gas tensions, Q br, and bronchial vascular resistance. Measurements were obtained during stable periods. There were no changes in pulmonary arterial pressure, cardiac output, arterial CO 2 tension, and arterial O 2 tension during the study. Blood pressure and Q br were lower after vagotomy compared with prevagotomy and after administration of L-NNA and after atropine (P Ͻ 0.05). pH was lower after vagotomy (P Ͻ 0.05) and returned to prevagotomy values by the end of the experiment.
Excised Airways
Results, expressed as mean Ϯ SE, are shown in Figs.  1 and 2 . Atropine abolished the contractile response to (Fig. 1 ) but were completely abolished in tissues pretreated with 1 µM propranolol (Fig. 2 ) or tetrodotoxin (P Ͻ 0.01).
DISCUSSION
The results of this study show that vagal stimulation in the sheep causes bronchoconstriction and bronchial arterial dilation in vivo. After cholinergic blockade, electrical field stimulation in vitro caused tracheal smooth muscle relaxation. These neural effects were not altered by NOS inhibitors, suggesting that NO is not mediating or influencing these responses. In contrast, the bronchial vascular dilation and the airway smooth muscle relaxation in vitro were completely blocked by administration of atropine and propranolol, respectively. These results imply that release of ACh mediates bronchial vascular dilation by a pathway that does not involve the generation of NO. In addition, these results show that the neural component of airway smooth muscle relaxation in sheep can be entirely explained by catecholamine release from autonomic nerve endings. It is apparent that these responses are different in the sheep from responses in several other species (1, 3, 4, 7, 17) , thus emphasizing the differences between species in the neural control of airway and bronchial vascular smooth muscle.
Bronchial Vascular Smooth Muscle
The decrease in Q br observed after vagotomy suggests that intact vagal innervation may be important for maintaining normal bronchial vascular tone. The effects of NO inhibitors on bronchial vascular smooth muscle relaxation are complex. As has been previously shown in our laboratory (12) , the administration of L-NNA produces a substantial fall in the baseline bronchial arterial blood flow; this makes it difficult to interpret the comparison of subsequent vasodilatory stimuli. In this study, vagal stimulation produced a significant increase in bronchial arterial blood flow after vagotomy and administration of L-NNA. Although the absolute increase in blood flow produced by vagal stimulation was attenuated by administration of L-NNA, the percent increase was not. However, because the baseline Q br was considerably less after administration of L-NNA, a comparison of the absolute increase in Q br is not strictly valid. To address this concern, we administered intra-arterial phenylephrine in a dosage sufficient to produce a comparable reduction in baseline bronchial arterial blood flow. In a previous study from this laboratory (12) , phenylephrine and L-NNA were given to reduce Q br by a similar amount before injection of ACh into the bronchial artery. Pretreatment with L-NNA was shown to attenuate significantly both the absolute and the percent increases in Q br compared with the increase after pretreatment with phenylephrine. We interpreted the different responses to ACh to imply that ACh caused the bronchial vascular dilation through release of NO. In the present study, the increase in Q br after vagal stimulation seen after L-NNA was compared with that seen after administration of phenylephrine. There was no significant difference in the absolute and percent increases in blood flow under these conditions. To the extent that there is not an interaction of vagal stimulation with the vasoconstriction caused by NOS inhibition or phenylephrine, these results suggest that inhibition of NOS did not influence the vagally induced vasodilation and, therefore, that NO was not an important mediator of the response.
There are at least three possible ways in which NO could be involved in bronchial vasodilation. First, postganglionic nerves innervating the bronchial vasculature (16) could contain NO as a neurotransmitter. Second, ACh released from postganglionic cholinergic nerves could release NO from tissue cells such as the bronchial vascular endothelium or smooth muscle. Third, NO could be acting at peribronchial ganglia, influencing postganglionic excitation. The fact that inhibition of NOS did not attenuate the bronchial vasodilation would seem to negate all three possible Values are means Ϯ SD; n, no. of animals. Q br, bronchial blood flow (in ml/min); BVR, bronchial vascular resistance (in mmHg · ml Ϫ1 · min). * Peak Q br Ͼ baseline and peak BVR Ͻ baseline, P Ͻ 0.01; † baseline Q br Ͼ and baseline BVR Ͻ during periods 2, 3, and 4, P Ͻ 0.01. ‡ Q br and BVR %change Ͻ during periods 1, 2, and 3, P Ͻ 0.01. Our results, relating to the effects of vagal nerve stimulation on bronchial arterial blood flow, are both in agreement with and at variance with the literature. Vagal nerve stimulation has been shown to cause bronchial vasodilation in cats and pigs (10, 11) . However, in these species, the effect was not completely blocked by atropine. We cannot comment on the potential involvement of prostanoids in the in vivo airway or vascular responses, because the sheep in the present study were pretreated with ibuprofen in accordance with previous methodology (12) . Because neurotransmitters released from vagal nerve endings may simultaneously affect bronchial vascular and airway smooth muscle tone, we also measured airway narrowing and tracheal smooth muscle contraction in the present studies.
Airway Smooth Muscle In Vivo
The NOS inhibitor L-NNA had no effect on the bronchoconstriction produced by vagal nerve stimulation, as measured by the change in RL. We had postulated that if vagal nerve stimulation caused release of NO, then attenuation of the NOS by L-NNA would cause enhanced bronchoconstriction. This negative in vivo finding is consistent with the in vitro studies that showed no evidence of a NANC inhibitory system.
Airway Smooth Muscle In Vitro
The present results clearly show that there is no inhibitory NANC innervation of ovine trachealis muscle and that neurally induced relaxation is adrenergically mediated. A single inhibitory adrenergic innervation of airway smooth muscle appears to be unique to sheep, compared with all the other species studied to date. There is considerable evidence to suggest that NO released from inhibitory NANC nerves is the principal neural mediator of airway smooth muscle relaxation in several species (1, 4, 6, 7, 17) . NO accounts for the inhibitory NANC response in peripheral and central human airways (1, 5) , and results from in vitro studies of guinea pig trachealis muscle show that NO accounts for ϳ50% of the inhibitory NANC response (9, 16) . Similarly, NO seems to be the principal inhibitory NANC mediator in pig tracheal smooth muscle because neural relaxation was completely inhibited after administration of L-NNA and was reversed by L-arginine, a substrate for NOS (7) . Similarly, NO has been shown to be the primary mediator of NANC relaxation in the cat trachealis muscle (6). Values are means Ϯ SD. BP, mean systemic arterial blood pressure; Ppa, mean pulmonary arterial pressure; CO, cardiac output; Pa CO 2 , arterial CO 2 tension; Pa O 2 , arterial O 2 tension. * Different from postvagotomy, P Ͻ 0.01; † Different from prevagotomy, pre-L-NNA, postatropine, P Ͻ 0.05. Fig. 1 . Effect of N G -nitro-L-arginine (L-NNA; 0.1 mM) on relaxation response of ovine trachealis smooth muscle. In 1982, Sheller and Brigham (13) demonstrated the presence of neural ␤-adrenergic airway smooth muscle relaxation in sheep. They found that electrical field stimulation in the presence of atropine produced a frequency-dependent relaxation of serotonin-induced tension in tracheal segments and bronchial rings. The relaxation was diminished after administration of propranolol (10 Ϫ6 M) or guanethidine (10 Ϫ5 M). They could not assess the contribution of NO, because at that time it had not been identified as a neurotransmitter. The results of the present study confirm the presence of a dominant ␤-adrenergic relaxation of ovine airway smooth muscle and demonstrate that NO is not involved in this response. Although we did not systematically study bronchi in the sheep, we did examine several specimens and found similar results.
In conclusion, the results of the present study indicate significant interspecies differences in the neurotransmitters that mediate airway smooth muscle and bronchial smooth muscle relaxation.
